HLTH News and Press, Cue Health Inc. From 08/04/23

2023-08-04 08:18:04 ET More on Cue Health FDA approves Cue Health's at-home COVID-19 test Cue Health downgraded to neutral at Goldman Sachs on post-COVID environment Cue Health wins FDA emergency nod for mpox test Cue Health partners with Pfizer on providing ...

The test will be designed to detect and differentiate between the four viruses and deliver results in approximately 25 minutes Cue Health (Nasdaq: HLTH), a healthcare technology company, today announced that it has been awarded a new approximately $28 million contract by the Biomedica...

Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its second quarter 2023 financial results on Wednesday, August 9, 2023. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pa...

2023-06-06 17:24:32 ET The U.S. Food and Drug Administration (FDA) on Tuesday said it had approved Cue Health's ( NASDAQ: HLTH ) at-home COVID-19 test, the first ever to be granted authorization through a traditional premarket review process. HLTH stock was down 4% to $0.57 ...

Cue’s COVID-19 Molecular Test detects all known variants of concern and seamlessly integrates with Cue Care, the company’s innovative test-to-treatment platform Cue Health (Nasdaq: HLTH), a healthcare technology company, announces an industry breakthrough as the first co...

Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will present at the Goldman Sachs 44 th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 4:00 p.m. Pacific Time at the Waldorf Astoria Monarch Beach Res...

2023-05-10 20:49:11 ET Cue Health, Inc. (HLTH) Q1 2023 Earnings Conference Call May 10, 2023 04:30 PM ET Company Participants Lorna Williams - IR Ayub Khattak - Co-Founder, President, CEO & Chairman Aasim Javed - CFO Conference Call Participants G...

2023-05-10 16:22:18 ET Cue Health press release ( NASDAQ: HLTH ): Q1 Non-GAAP EPS of -$0.48 beats by $0.13 . Revenue of $24.76M (-86.2% Y/Y) beats by $1.74M . Cue Health expects second quarter 2023 revenues in the range of $8 million to $10 million vs $20.98M c...

Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the first quarter 2023. Recent Highlights Reported first quarter revenue of $24.8 million Granted U.S. Food and Drug Administration (FDA) Emergency Use Authorization (...

Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced that it has made a De Novo submission to the U.S. Food and Drug Administration (FDA) for full clearance of the Cue RSV Molecular Test for at-home and point-of-care use. There are currently no respira...